Publicaciones en las que colabora con Manuel Segovia Hernández (12)

2020

  1. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

    The Lancet, Vol. 396, Núm. 10250, pp. 535-544

2014

  1. Prevalence of plasmid-mediated quinolone resistance determinants in extended-spectrum β-lactamase-producing and -non-producing enterobacteria in Spain

    International Journal of Antimicrobial Agents

2009

  1. Actividad in vitro de fosfomicina frente a enterobacterias de origen urinario productoras de betalactamasas de espectro extendido

    Revista Espanola de Quimioterapia, Vol. 22, Núm. 1, pp. 25-29

2004

  1. In vitro activity of older and newer fluoroquinolones against efflux-mediated high-level ciprofloxacin-resistant Streptococcus pneumoniae

    International Journal of Antimicrobial Agents, Vol. 24, Núm. 2, pp. 185-187

2003

  1. In vitro activity of newer antibiotics against Corynebacterium jeikeium, Corynebacterium amycolatum and Corynebacterium urealyticum

    International Journal of Antimicrobial Agents, Vol. 22, Núm. 5, pp. 492-496

2002

  1. In vitro activity of linezolid, synercid and telithromcin against genetically defined high level fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus

    International Journal of Antimicrobial Agents, Vol. 20, Núm. 1, pp. 61-64

2001

  1. Molecular diversity of quinolone resistance in genetically related clinical isolates of Staphylococcus aureus and susceptibility to newer quinolones

    Journal of Antimicrobial Chemotherapy, Vol. 47, Núm. 2, pp. 157-161

2000

  1. Actividad de nuevas quinolonas frente a aislamientos clinicos de Corynebacterium spp

    Revista Espanola de Quimioterapia, Vol. 13, Núm. 3, pp. 267-270

  2. Actividad in vitro de nuevas quinolonas frente a cepas clinicas de Staphylococcus aureus silvestres y con mutaciones caracterizadas e n gyrA, gyrB y grlA

    Revista Espanola de Quimioterapia, Vol. 13, Núm. 3, pp. 271-275

1999

  1. Efflux pump-mediated quinolone resistance in staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA

    Antimicrobial Agents and Chemotherapy, Vol. 43, Núm. 2, pp. 354-356

  2. In vitro activities of 13 fluoroquinolones against Staphylococcus aureus isolates with characterized mutations in gyrA, gyrB, grlA, and norA and against wild-type isolates

    Antimicrobial Agents and Chemotherapy, Vol. 43, Núm. 4, pp. 966-968

1998

  1. Analysis of grlA mutations in clinical isolates of Staphylococcus aureus with different levels of quinolone resistance [3]

    Antimicrobial Agents and Chemotherapy